Study Investigating Safety,Tolerability,Pharmacokinetics and Antitumor Activities of HBM4003 Combine With Toripalimab

NCT04727164 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: HBM4003 and Triprilimab

Sponsor

Harbour BioMed (Guangzhou) Co. Ltd.